Membranoproliferative Glomerulonephritis: Clinical Considerations about a Case

Abstract

During the last decade, the classification and clinical approach of primary membranoproliferative glomerulonephritis have dramatically been changed. New proposed classification led to the individualization of a new entity, C3 glomerulopathy defined by exclusive or predominant glomerular C3 deposits. Complement workup helped in defining the place of constitutional and acquired dysregulation of the complement alternative pathway in the pathogenesis of these nephropathies. Finally, these advances have coincided with the availability of the first complement inhibitor, eculizumab, and the development of a growing number of complement modulators, paving the way for specific treatments of these severe renal diseases.